Sciety

What they fund

• Stage — Seed-stage life science and digital health companies with strong growth potential [1].
• Sector — Biopharma, precision medicine, digital health solutions, and medical technology [1].
• Geography — Primarily Nordic region, with a focus on Swedish and European markets [1].
• Shape — Companies with innovative technologies addressing unmet medical needs, such as precision oncology and pain management [1].

Credibility: Investment criteria and portfolio composition are detailed on the Sciety website, highlighting their focus on early-stage, high-impact ventures [1].

Investment thesis

Sciety invests alongside partners in exceptional life science and digital health companies, leveraging strong deal flow and rigorous selection processes.

• Impact and Return — The philosophy is that financial return and impact should go hand in hand, aiming for companies that make a real difference in people’s lives.
• Market Drivers — Investments are driven by an aging population, increasing incidence of lifestyle diseases, demanding healthcare consumers, and the biotechnological revolution enabling precision medicine and genomics [1].
• Active Ownership — They believe active ownership is key to creating value, remaining engaged and committed to companies well beyond the financing round [1].
• Skin in the Game — They align their interests with founders by investing their own capital alongside LPs, ensuring deep commitment to portfolio success.

Credibility: The thesis is articulated on the Sciety homepage and investor materials, emphasizing long-term value creation through active engagement and rigorous selection [1].

Value add

Sciety provides active ownership, long-term engagement, and strategic support to portfolio companies. They assist with board strengthening, customer introductions, and preparation for future funding rounds or exits.

Fit verdict: Ideal for founders seeking a partner with deep industry expertise and a long-term commitment to growth.

Founder diligence script:

• How does Sciety typically engage with the board during the first 12 months?
• What specific resources do they provide to help with customer acquisition?
• How do they support companies in preparing for Series A or strategic partnerships?
• What is their track record in helping companies navigate regulatory hurdles?
• How do they measure success beyond financial returns?

Credibility: Value-add services are described on the Sciety website, emphasizing their role as a long-term partner [1].

Portfolio focus

• Moroxite AB — Developing innovative bone substitutes for spinal surgery to improve healing and reduce complications [1].
• Pharmnovo AB — Clinical-stage company developing treatments for neuropathic pain with potential blockbuster applications [1].
• PeptiSystems — Specializes in large-scale production of precision drugs and manufacturing instruments for peptides and oligonucleotides [1].
• Akiram Therapeutics — Focuses on targeted radioimmunotherapy for cancer treatment [1].

Credibility: Portfolio companies are listed on the Sciety website under 'Companies we are investing in right now' and 'Completed investments' [1].

Notable investments & exits

• PeptiSystems — Sold instruments for pharmaceutical manufacturing, indicating a successful exit [1].
• Akiram Therapeutics — Developed targeted radioimmunotherapy, potentially leading to an acquisition or IPO [1].

Credibility: Notable exits are inferred from the Sciety website's completed investments and company descriptions [1].

Strategic implications

Sciety's focus on the Nordic life sciences sector positions it as a key player in a region known for innovation and R&D investment. Their emphasis on active ownership and long-term engagement suggests a strategy focused on deep value creation rather than quick exits. The signal to watch is their ability to scale their co-investor network and maintain deal flow in a competitive market.

Where they could go further

Sciety could expand its geographic focus to include more European markets to diversify its portfolio. They could enhance their digital health offerings by partnering with tech-focused VCs. Increasing transparency around fund performance and exit outcomes would strengthen their appeal to LPs. Developing a more structured mentorship program for founders could further differentiate their value proposition.